Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Biovin Enterprises LLC

Neither a doctor nor a teaching hospital

Research payments

$11,929,619

1,484 payments

Through program year 2025, Biovin Enterprises LLC is reported as receiving $11,929,619 in research payments, across 1,484 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,478,162 145
2024 Research $1,403,898 170
2023 Research $1,349,529 160
2022 Research $944,375 338
2021 Research $1,570,560 233
2020 Research $1,663,877 252
2019 Research $1,519,219 186

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,773,831 162 payments
  2. GlaxoSmithKline, LLC. $2,031,129 406 payments
  3. AbbVie, Inc. $2,025,707 426 payments
  4. Amgen Inc. $1,441,411 15 payments
  5. Gilead Sciences, Inc. $1,133,997 98 payments
  6. Sun Pharmaceutical Industries Inc. $288,932 100 payments
  7. Pfizer Inc. $228,599 59 payments
  8. Sanofi US Services Inc. $211,454 30 payments
  9. Janssen Research & Development, LLC $169,469 62 payments
  10. Novartis Pharmaceuticals Corporation $150,227 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $1,025,619 5 payments
  2. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $907,590 41 payments
  3. A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $670,065 43 payments
  4. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $588,686 17 payments
  5. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $535,943 63 payments
  6. A Phase 2B Double Blind Placebo Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis $470,462 6 payments
  7. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $467,243 174 payments
  8. M15-572 $441,622 48 payments
  9. A Phase 2B Double Blind Placebo Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis $427,033 9 payments
  10. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $357,668 123 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record